Effect of polypeptide CH50 on macrophage activation in vivo and anti-tumor function.
The main features of CH50, a recombinant polypeptide of human fibronectin, activating macrophages in vivo and its anti-tumor function were investigated. After injection of CH50 and(or) transfection of IFN-gamma gene in vivo, several kinds of factors produced by macrophages were determined and the growth of tumor in vivo was measured. CH50 could enhance the production of such factors as NO, TNF and IL-1 by macrophages, but the activation of macrophages was relatively slow when CH50 was used in vivo alone. CH50 and IFN-gamma could synergistically activate macrophages rapidly in vivo no matter whether the injection of CH50 or the transfection of IFN-gamma gene was performed first. Injection of CH50 alone inhibited the formation of tumor nodes in a dose-dependent manner. Low dose of CH50 could strongly inhibit the formation of tumor nodes less than 1 mm, while high dose of CH50 could inhibit those more than 1 mm. A stronger inhibition on the growth of tumor in vivo was obtained by the synergistic effect of CH50 and IFN-gamma. CH50 and IFN-gamma, as double-signal factors for activation of macrophages, will be potentially useful in tumortherapy.
Zhang
G
G
Department of Medical Molecular Biology, Tongji Medical University, Wuhan 430030.
Feng
Z
Z
Li
D
D
Zhang
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005353:Fibronectins / Q000494:pharmacology*; D007371:Interferon-gamma / Q000235:genetics; D008262:Macrophage Activation / Q000187:drug effects*; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D010455:Peptides / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D005353:Fibronectins; D010455:Peptides; D011994:Recombinant Proteins; D007371:Interferon-gamma